HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection

BACKGROUND: DRα1-mouse(m)MOG-35-55, a novel construct developed in our laboratory as a simpler and potentially less immunogenic alternative to two-domain class II constructs, was shown previously to target the MIF/CD74 pathway and to reverse clinical and histological signs of experimental autoimmune...

Descripción completa

Detalles Bibliográficos
Autores principales: Benedek, Gil, Meza-Romero, Roberto, Jordan, Kelley, Keenlyside, Lucy, Offner, Halina, Vandenbark, Arthur A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481122/
https://www.ncbi.nlm.nih.gov/pubmed/26104759
http://dx.doi.org/10.1186/s12974-015-0342-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481122/
https://www.ncbi.nlm.nih.gov/pubmed/26104759
http://dx.doi.org/10.1186/s12974-015-0342-4

Ejemplares similares